Nuzzi R, Geronazzo G, Tridico F, et al. - Researchers conducted this prospective cohort study to assess eye structures and function in patients receiving iron chelating therapy and to see if there is a link between the onset of ocular alterations and the use of iron chelating drugs. Eighty patients [18 children and 62 adults] with thalassemia major who are or have been taking iron chelating drugs (deferoxamine, deferiprone, or deferasirox) were enrolled in the study. No association was found between iron chelation therapy and severe visual function alterations. Deferoxamine treatment limits can help prevent ocular complications. Deferiprone and/or deferasirox may be preferable in patients over the age of 40.